sanofi-aventis
Sanofi-aventis Stands Behind the Safety of Lantus(R)
Published in Medicine and Law Weekly, July 17th, 2009
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) has just been made aware of data associated with a retrospective follow-up of four patient registries. The results of these data clearly show that no definitive conclusions can be drawn regarding a possible causal relationship between Lantus(R) (insulin glargine [rDNA] injection) use and the occurrence of malignancies, as the authors of the study point out.
Clinical studies, which represent the gold standard of evidence, do not indicate an association between insulin glargine and cancer.
"Given the extensive clinical evidence covering over 70,000 patients and the results of post-marketing surveillance...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
More Articles from Medicine and Law Weekly
- Behavior
Studies from Yale University, Medical Department provide new data on behavior - Gastroenterology
New gastroenterology research reported from William Beaumont Hospital, Division of Gastroenterology - Health Insurance
Research on health insurance discussed by E. Heeley and co-researchers - Life Sciences
New life sciences research reported from University of Modena - Life Sciences
Report summarizes life sciences study findings from University of Wisconsin - Life Sciences
Research findings from R. Horn et al update understanding of life sciences - More from this issue of Medicine and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
